Highlights from TOBI 2017

What is TOBI?

Opportunity to… learn, connect, grow
Platform to… speak, share, inspire


The Conference where it all comes together.
TOBI 2018 is our 9th Annual gathering of orthobiologics thought-leaders from around the globe. Attending TOBI puts you on the cutting edge with the latest research and clinical pearls in orthopedic regenerative medicine. TOBI empowers you to build relationships with other physicians, researchers and scientists on the forefront of regenerative medicine. Engaging in the TOBI community provides you a platform to share your expertise with like-minded clinicians. Join us to cultivate your thought leadership, and strengthen your network in one of medicine’s fastest growing fields.

9th Annual PRP & Regenerative Medicine Symposium, Workshops & Cadaver Lab - June 7-9, 2018, WYNN, LAS VEGAS

TOBI News

Biologic Treatments Get the Attention of AAOS in Current Issue

As research accumulates to support and build data behind biologic treatments, mainstream orthopedic organizations take note. The January issue of the leading orthopedic news magazine and the official magazine of the American Academy of Orthopedic Surgeons, AAOS NOW, featured a piece on biologic treatments becoming the standard of care in cartilage restoration. The article in AAOS [...]

Positive Results from Stem Cell Study on Knee Cartilage

A research study that began in May at the Andrews Institute in Gulf Breeze, FL, is yielding positive results that could “ultimately overhaul how doctors treat common joint maladies.” TOBI 2018 Faculty Adam Anz spearheaded this study that examines the efficacy of creating new cartilage in the knee through a series of stem cell injections. Anz [...]

AAOS Issues New Statement on Biologic Therapies; Endorses Registries

The American Association of Orthopedic Surgeons (AAOS) has issued a new statement on the use of emerging biologic therapies. Like much of the discussion regarding orthobiologics, the AAOS statement touches on the need for regulation regarding safety and effectiveness of new uses of biologic therapies, particularly during the “increasing shift to therapeutic biologic products for [...]

TOBI Faculty Andrew Ittleman on the FDA’s Regulation of Stem Cells

TOBI 2017 Faculty Andrew Ittleman, JD, has published a valuable article on how the FDA should regulate human cells. This article, which appeared in The Regulatory Review, provides a brief history of the FDA’s involvement in the regulation of human cells, starting with the Wall Street Journal Op-ed, “The FDA Wants to Regulate Your Cells“, [...]